MCID: ASP006
MIFTS: 65

Aspergillosis

Categories: Genetic diseases, Rare diseases, Infectious diseases, Bone diseases, Cardiovascular diseases, Respiratory diseases, Nephrological diseases, Eye diseases, Gastrointestinal diseases, Neuronal diseases

Aliases & Classifications for Aspergillosis

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 57 12 76 53 59 55 43 3 44 15 73
Aspergillosis, Susceptibility to 57 29 13 6 40
Infection Due to Aspergillus 12

Characteristics:

Orphanet epidemiological data:

59
aspergillosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

OMIM 57 614079
Disease Ontology 12 DOID:13564
ICD10 33 B44 B44.9
ICD9CM 35 117.3
MeSH 44 D001228
NCIt 50 C2886
Orphanet 59 ORPHA1163
MESH via Orphanet 45 D001228
UMLS via Orphanet 74 C0004030
ICD10 via Orphanet 34 B44.0 B44.1 B44.2 more
UMLS 73 C0004030

Summaries for Aspergillosis

NIH Rare Diseases : 53 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain).Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary : Aspergillosis, also known as aspergillosis, susceptibility to, is related to invasive aspergillosis and allergic bronchopulmonary aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Miconazole and Voriconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and kidney, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney,heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

OMIM : 57 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079)

MedlinePlus : 43 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

CDC : 3 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Wikipedia : 76 Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus... more...

Related Diseases for Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 410)
# Related Disease Score Top Affiliating Genes
1 invasive aspergillosis 32.0 CD79A CLEC7A IFNG SFTPD TLR2 TLR4
2 allergic bronchopulmonary aspergillosis 31.4 CCL17 CFTR IL4 IL5 MBL2 SFTPA2
3 hematopoietic stem cell transplantation 31.2 CLEC7A IFNG IL10
4 pneumocystosis 30.3 CD79A CLEC7A SFTPD
5 candidiasis 30.2 CD79A CLEC7A IFNG IL10
6 cough variant asthma 30.1 IL4 IL5
7 septic arthritis 30.1 IFNG TLR2 TLR4
8 eosinophilic pneumonia 30.1 CCL17 IL5 SFTPD
9 hyper ige syndrome 30.0 IFNG IL4 TLR2
10 acute graft versus host disease 30.0 IFNG IL10 IL4
11 wegener granulomatosis 30.0 ELANE IFNG IL10
12 lepromatous leprosy 30.0 IFNG IL10 TLR2
13 rhinitis 29.9 IL4 IL5 TLR9
14 cryptococcosis 29.9 IFNG IL4 MBL2 TLR9
15 churg-strauss syndrome 29.8 CCL17 IL10 IL5
16 cutaneous t cell lymphoma 29.8 CCL17 IFNG IL4
17 acquired immunodeficiency syndrome 29.8 CD79A IFNG IL10
18 farmer's lung 29.7 CD79A ELANE
19 chronic graft versus host disease 29.7 CD79A IFNG IL10
20 allergic rhinitis 29.7 IFNG IL10 IL4 IL5
21 extrinsic allergic alveolitis 29.5 CD79A IL10 SFTPD
22 gastroenteritis 29.5 IFNG IL10 IL4 IL5
23 dermatitis 29.5 CCL17 IFNG IL4 IL5
24 crohn's disease 29.4 IL10 TLR4 TLR9
25 pulmonary eosinophilia 29.3 CCL17 IL4 IL5 SFTPD
26 colitis 29.2 IFNG IL10 IL4 TLR4 TLR9
27 pulmonary tuberculosis 29.1 IFNG IL10 IL4 MBL2 TLR2 TLR9
28 toxic shock syndrome 29.1 IFNG IL10 IL4 TLR2 TLR4
29 meningitis 29.1 IFNG IL10 MBL2 TLR2 TLR9
30 interstitial lung disease 29.0 CCL17 IFNG IL10 IL4 SFTPD
31 bronchiectasis 29.0 CFTR ELANE MBL2 TLR2
32 pulmonary disease, chronic obstructive 29.0 CFTR ELANE SFTPD TLR2
33 psoriasis 28.7 CCL17 IFNG IL10 IL4 TLR9
34 cystic fibrosis 28.7 CCL17 CFTR ELANE MBL2 SFTPD TLR4
35 paranasal sinus disease 28.6 CD79A IFNG IL10 IL4 IL5
36 rheumatoid arthritis 28.6 CD79A IFNG IL10 IL4 TLR2 TLR4
37 systemic lupus erythematosus 28.4 CD79A IFNG IL10 IL4 MBL2 TLR9
38 bronchiolitis 28.3 IFNG IL10 IL4 IL5 TLR4 TLR9
39 common variable immunodeficiency 28.0 CD79A IFNG IL10 IL4 MBL2 TLR9
40 pneumonia 27.9 ELANE IL10 IL5 MBL2 SFTPD TLR2
41 leishmaniasis 27.7 IFNG IL10 IL4 IL5 TLR2 TLR4
42 dermatitis, atopic 27.7 CCL17 IFNG IL10 IL4 IL5 TLR2
43 bronchitis 27.6 CD79A CFTR ELANE IL5
44 lung disease 26.2 CFTR ELANE IL10 IL5 SFTPA2 SFTPD
45 asthma 25.5 CCL17 CD79A CFTR ELANE IFNG IL10
46 allergic bronchopulmonary aspergillosis, familial 12.1
47 pulmonary aspergilloma 11.2
48 mycoplasmal pneumonia 10.9 IFNG IL4
49 neuroaspergillosis 10.9
50 plastic bronchitis 10.9

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):


Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:



Diseases related to Aspergillosis

Symptoms & Phenotypes for Aspergillosis

Clinical features from OMIM:

614079

UMLS symptoms related to Aspergillosis:


fever, pruritus

MGI Mouse Phenotypes related to Aspergillosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 CCL17 CD79A CFTR CLEC7A ELANE IFNG
2 homeostasis/metabolism MP:0005376 10.22 CD79A CFTR CLEC7A ELANE IFNG IL10
3 immune system MP:0005387 10.21 CD79A CFTR CLEC7A ELANE IFNG IL10
4 digestive/alimentary MP:0005381 10.11 TLR4 TLR9 CFTR CLEC7A IFNG IL10
5 liver/biliary system MP:0005370 9.92 IL5 TLR2 TLR4 CD79A CFTR IFNG
6 neoplasm MP:0002006 9.8 CD79A ELANE IFNG IL10 IL5 TLR2
7 normal MP:0002873 9.76 CD79A CFTR ELANE IFNG IL10 IL4
8 renal/urinary system MP:0005367 9.5 CD79A IFNG IL4 MBL2 TLR2 TLR4
9 respiratory system MP:0005388 9.28 CFTR CLEC7A IFNG IL10 IL4 IL5

Drugs & Therapeutics for Aspergillosis

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
2
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616
3
Amphotericin B Approved, Investigational Phase 4,Phase 2,Phase 3 1397-89-3 14956 5280965
4
Caspofungin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Itraconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 84625-61-6 55283
7
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
8
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 235114-32-6 3081921 477468
9
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
10
Nevirapine Approved Phase 4 129618-40-2 4463
11
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
12
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
13
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1 128794-94-5 5281078
14
Mycophenolic acid Approved Phase 4,Phase 1 24280-93-1 446541
15
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
16
Omalizumab Approved, Investigational Phase 4 242138-07-4
17
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 50-14-6 5280793
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 1406-16-2
19
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 67-97-0 6221 5280795
20 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Liposomal amphotericin B Phase 4,Phase 2,Phase 3
32 Echinocandins Phase 4,Phase 3,Phase 2,Phase 1
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antitussive Agents Phase 4
35 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
36
Hydroxyitraconazole Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
37 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Ergocalciferols Phase 4,Phase 2,Phase 3,Not Applicable
39 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
40 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
41 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
42 Anti-HIV Agents Phase 4,Phase 3
43 Anti-Retroviral Agents Phase 4,Phase 3
44 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Atazanavir Sulfate Phase 4
46 Cytochrome P-450 CYP3A Inducers Phase 4
47 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
48 HIV Protease Inhibitors Phase 4,Phase 3
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 1
50
protease inhibitors Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 Voriconazole for IPA in Chinese Patients With COPD Unknown status NCT02234739 Phase 4 Voriconazole
2 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
5 COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis Completed NCT00334412 Phase 4 Ambisome;caspofungin
6 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
7 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
8 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
9 VITamine D Supplementation in RenAL Transplant Recipients - VITALE Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
10 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
11 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
12 King's Invasive Aspergillosis Study II Not yet recruiting NCT02875743 Phase 4 Posaconazole
13 Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
14 Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Terminated NCT02646774 Phase 4 Micafungin
15 An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
16 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
17 Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia Terminated NCT00190463 Phase 4 Amphotericin B
18 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
19 A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
20 Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection. Withdrawn NCT02020213 Phase 4 Posaconazole
21 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis Unknown status NCT01125644 Phase 3 SPK-843
22 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
23 Voriconazole For Chronic Bronchopulmonary Aspergillosis Completed NCT00159822 Phase 2, Phase 3 Voriconazole
24 Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
25 A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients Completed NCT00163722 Phase 3
26 Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids;Glucocorticoids
27 A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
28 Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
29 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Completed NCT00634049 Phase 3 isavuconazole
30 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
31 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
32 Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
33 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
34 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
35 Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment Completed NCT00158730 Phase 3 AmBisome
36 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
37 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
38 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
39 Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Completed NCT00001937 Phase 3 FK463;Fluconazole
40 Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) Completed NCT00034658 Phase 3 Posaconazole
41 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
42 Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Completed NCT00177684 Phase 3 Amphotericin B
43 Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) Completed NCT00034632 Phase 3 Posaconazole oral suspension
44 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
45 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001757 Phase 3 Voriconazole
46 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
47 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
48 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
49 Voriconazole to Treat Fungal Infections Completed NCT00001940 Phase 3 Voriconazole
50 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Completed NCT00627393 Phase 3 Standard antimicrobial therapy;G-CSF/dexamethasone

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: aspergillosis

Genetic Tests for Aspergillosis

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 29 CLEC7A

Anatomical Context for Aspergillosis

MalaCards organs/tissues related to Aspergillosis:

41
Lung, Testes, Kidney, Bone, Brain, Liver, Heart

Publications for Aspergillosis

Articles related to Aspergillosis:

(show top 50) (show all 1943)
# Title Authors Year
1
The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. ( 29687483 )
2018
2
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. ( 29750016 )
2018
3
National Jewish Health Classical Pulmonary Radiology Case Reports: Imaging Features of Allergic Bronchopulmonary Aspergillosis. ( 29878247 )
2018
4
Performance of serum (1,3)-A9-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. ( 29693758 )
2018
5
Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: a case report. ( 29408183 )
2018
6
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
7
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. ( 29950869 )
2018
8
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. ( 29437588 )
2018
9
Risk Factors and impact of Allergic Bronchopulmonary Aspergillosis in P. aeruginosa negative CF Patients. ( 29981532 )
2018
10
Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis. ( 29566248 )
2018
11
Subacute invasive aspergillosis associated with sorafenib therapy for hepatocellular carcinoma. ( 29370392 )
2018
12
Predicting Invasive Aspergillosis in Hematology Patients by Combining Clinical and Genetic Risk Factors with Early Diagnostic Biomarkers. ( 29118175 )
2018
13
How we approach combination antifungal therapy for invasive aspergillosis and mucormycosis in transplant recipients. ( 29975240 )
2018
14
Vitamin D levels in asthmatic patients with and without allergic bronchopulmonary aspergillosis. ( 29314357 )
2018
15
Chitinase Induction Prior to Caspofungin Treatment of Experimental Invasive Aspergillosis in Neutropenic Rats Does Not Enhance Survival. ( 29084744 )
2018
16
Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities. ( 29105850 )
2018
17
Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. ( 29398462 )
2018
18
A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. ( 29331473 )
2018
19
X-linked agammaglobulinemia complicated with pulmonary aspergillosis. ( 29356289 )
2018
20
Pentraxin3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis. ( 29964232 )
2018
21
Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis. ( 29787890 )
2018
22
Clinical Characteristics of Fifty Patients with Allergic Bronchopulmonary Aspergillosis. ( 29692383 )
2018
23
Invasive aspergillosis in patients following umbilical cord blood transplant. ( 29795425 )
2018
24
Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. ( 29980664 )
2018
25
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )
2018
26
Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care. ( 29897826 )
2018
27
Allergic bronchopulmonary aspergillosis presenting as nephrotic syndrome due to secondary amyloidosis: Case report and systematic review of the literature. ( 29970774 )
2018
28
Sinonasal aspergillosis: Outcome after topical treatment in dogs with cribriform plate lysis. ( 29957889 )
2018
29
Diagnostic Aspects of Veterinary and Human Aspergillosis. ( 29977229 )
2018
30
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
31
Improved and adopted murine models to combat pulmonary aspergillosis. ( 29911293 )
2018
32
A case of allergic bronchopulmonary aspergillosis in a 43-year-old farmer following single high level exposure to organic dust with symptomatic remission and radiological resolution after early diagnosis and treatment. ( 29479448 )
2018
33
Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients: Performance of Cytokines, Asp LFD, and Aspergillus PCR in Same Day Blood and Bronchoalveolar Lavage Samples. ( 29972764 )
2018
34
The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review. ( 29727605 )
2018
35
Invasive Aspergillosis Mimicking Metastatic Lung Cancer. ( 29922593 )
2018
36
Utility of recombinant Aspergillus fumigatus antigens in the diagnosis of allergic bronchopulmonary aspergillosis: a systematic review and diagnostic test accuracy meta-analysis. ( 29927507 )
2018
37
Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. ( 29551015 )
2018
38
Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. ( 29670608 )
2018
39
Invasive Aspergillosis with Pulmonary and Central Nervous System involvement during ibrutinib therapy for relapsed Chronic Lymphocytic Leukaemia, a case report. ( 29427802 )
2018
40
Treatment of Sinonasal Aspergillosis by Debridement and Sinonasal Deposition Therapy with Clotrimazole Under Rhinoscopic Guidance. ( 29372867 )
2018
41
Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013. ( 29718296 )
2018
42
Characterisation of the cellular and proteomic response of Galleria mellonella larvae to the development of invasive aspergillosis. ( 29954319 )
2018
43
Is it time for systematic voriconazole pharmacogenomic investigation for central nervous system aspergillosis? ( 29967027 )
2018
44
Low sensitivity of Lateral Flow Device-<i>Aspergillus</i>in patients with probable and proven aspergillosis: results from a multicentre evaluation. ( 29444833 )
2018
45
Outbreak of invasive aspergillosis in heart transplant recipients: The role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis. ( 29125713 )
2018
46
CT findings of fungal pneumonia with emphasis on aspergillosis. ( 29956050 )
2018
47
Mutations in EEA1 are associated with allergic bronchopulmonary aspergillosis and affect phagocytosis of Aspergillus fumigatus by human macrophages. ( 29547649 )
2018
48
Massive haemoptysis secondary to mycotic pulmonary artery aneurysm in subacute invasive aspergillosis. ( 29674397 )
2018
49
Diagnostic cut-off of A.fumigatus-specific IgG in the diagnosis of chronic pulmonary aspergillosis. ( 29920796 )
2018
50
Asthma and Fungus: Role in Allergic Bronchopulmonary Aspergillosis (ABPA) and Other Conditions. ( 29549557 )
2018

Variations for Aspergillosis

Expression for Aspergillosis

Search GEO for disease gene expression data for Aspergillosis.

Pathways for Aspergillosis

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 CD209 CD79A CLEC7A ELANE IFNG IL10
2
Show member pathways
13.34 CCL17 IL10 IL4 IL5 TLR2 TLR4
3
Show member pathways
12.93 IFNG IL10 MBL2 SFTPA2 SFTPD TLR2
4
Show member pathways
12.77 CD79A IFNG IL4 TLR2 TLR4 TLR9
5
Show member pathways
12.76 CD209 IFNG IL4 TLR2 TLR4 TLR9
6
Show member pathways
12.57 IFNG IL10 IL4 IL5
7 12.5 CD79A IFNG IL10 IL4 TLR2 TLR9
8
Show member pathways
12.39 IFNG IL10 IL4 IL5 TLR2 TLR4
9
Show member pathways
12.38 IFNG IL10 IL4 IL5
10
Show member pathways
12.24 CCL17 CFTR IFNG IL4 IL5 TLR2
11
Show member pathways
12.23 IFNG IL10 TLR2 TLR4 TLR9
12
Show member pathways
12.22 IFNG IL10 IL4 TLR2 TLR4
13 12.16 IFNG TLR2 TLR4 TLR9
14
Show member pathways
12.16 CCL17 CD209 CLEC7A IL10 TLR9
15
Show member pathways
12.05 CCL17 IFNG IL10 IL4 IL5
16
Show member pathways
12.01 IL5 TLR2 TLR4 TLR9
17 11.95 CD209 CLEC7A IFNG IL10 TLR2 TLR4
18 11.93 IFNG IL4 TLR4
19 11.89 IFNG IL10 TLR2 TLR4
20 11.82 CLEC7A TLR2 TLR4 TLR9
21 11.8 IFNG TLR2 TLR4
22 11.8 CD209 CD79A IFNG IL10 IL4 IL5
23 11.78 IFNG IL10 IL4 IL5
24 11.76 IFNG IL4 IL5
25 11.74 CD209 IFNG IL10 TLR9
26
Show member pathways
11.72 IFNG IL4 IL5
27 11.72 IL10 SFTPA2 TLR4
28
Show member pathways
11.72 CFTR IFNG IL4 SFTPD TLR2 TLR4
29 11.64 CCL17 IL10 IL4 IL5
30 11.63 IL4 IL5 SFTPA2
31 11.5 IFNG TLR2 TLR4
32 11.46 IFNG IL10 TLR2 TLR4 TLR9
33 11.38 CCL17 IFNG IL10 IL4 IL5
34 11.35 IFNG IL10 TLR9
35 11.35 CD209 CLEC7A MBL2 SFTPA2 SFTPD TLR2
36 11.32 IFNG IL4 IL5
37 11.3 IFNG IL4 IL5
38 11.23 IFNG IL10 IL4 IL5
39 11.12 IFNG IL10 IL4 IL5

GO Terms for Aspergillosis

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 CD209 CFTR ELANE MBL2 TLR2 TLR4
2 extracellular space GO:0005615 9.65 CCL17 ELANE IFNG IL10 IL4 IL5
3 collagen trimer GO:0005581 9.54 MBL2 SFTPA2 SFTPD
4 extracellular region GO:0005576 9.36 CCL17 CD209 ELANE IFNG IL10 IL4
5 multivesicular body GO:0005771 9.33 CD79A SFTPA2 SFTPD
6 lamellar body GO:0042599 9.32 SFTPA2 SFTPD

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 CCL17 IFNG IL10 IL4 IL5 TLR2
2 response to lipopolysaccharide GO:0032496 9.94 ELANE IL10 TLR2 TLR4
3 positive regulation of inflammatory response GO:0050729 9.85 TLR2 TLR4 TLR9
4 B cell differentiation GO:0030183 9.84 CD79A IL10 IL4
5 positive regulation of interleukin-6 production GO:0032755 9.81 TLR2 TLR4 TLR9
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.81 TLR2 TLR4 TLR9
7 positive regulation of tumor necrosis factor production GO:0032760 9.8 TLR2 TLR4 TLR9
8 defense response to bacterium GO:0042742 9.8 ELANE IL10 MBL2 SFTPD TLR4 TLR9
9 inflammatory response GO:0006954 9.8 CCL17 CLEC7A IL10 IL5 TLR2 TLR4
10 positive regulation of phagocytosis GO:0050766 9.77 MBL2 SFTPA2 SFTPD
11 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.77 TLR2 TLR4 TLR9
12 positive regulation of interleukin-8 production GO:0032757 9.76 TLR2 TLR4 TLR9
13 negative regulation of interleukin-6 production GO:0032715 9.75 IL10 TLR4 TLR9
14 positive regulation of interferon-beta production GO:0032728 9.74 TLR2 TLR4 TLR9
15 positive regulation of interleukin-10 production GO:0032733 9.73 TLR2 TLR4 TLR9
16 positive regulation of B cell proliferation GO:0030890 9.73 IL4 IL5 TLR4 TLR9
17 positive regulation of chemokine production GO:0032722 9.72 TLR2 TLR4 TLR9
18 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 TLR2 TLR4 TLR9
19 negative regulation of growth of symbiont in host GO:0044130 9.7 ELANE IL10 MBL2
20 response to molecule of bacterial origin GO:0002237 9.69 IL10 TLR2 TLR9
21 defense response to protozoan GO:0042832 9.68 CLEC7A IL10
22 positive regulation of macrophage activation GO:0043032 9.68 IL10 TLR4
23 cellular response to lipoteichoic acid GO:0071223 9.68 TLR2 TLR4
24 negative regulation of interleukin-17 production GO:0032700 9.68 IFNG TLR4
25 surfactant homeostasis GO:0043129 9.67 SFTPA2 SFTPD
26 I-kappaB phosphorylation GO:0007252 9.67 TLR2 TLR4 TLR9
27 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.66 ELANE TLR4
28 positive regulation of interferon-beta biosynthetic process GO:0045359 9.66 TLR4 TLR9
29 type 2 immune response GO:0042092 9.65 IL10 IL4
30 negative regulation of interleukin-8 production GO:0032717 9.65 IL10 TLR9
31 regulation of cytokine secretion GO:0050707 9.65 TLR2 TLR4 TLR9
32 positive regulation of toll-like receptor signaling pathway GO:0034123 9.62 TLR2 TLR9
33 tumor necrosis factor production GO:0032640 9.62 TLR2 TLR9
34 regulation of isotype switching GO:0045191 9.61 IL10 IL4
35 positive regulation of interleukin-18 production GO:0032741 9.61 TLR2 TLR9
36 immune system process GO:0002376 9.56 CD209 CD79A CLEC7A MBL2 SFTPD TLR2
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.54 IL10 IL4 TLR4
38 positive regulation of interleukin-12 production GO:0032735 9.46 IFNG TLR2 TLR4 TLR9
39 toll-like receptor signaling pathway GO:0002224 9.02 SFTPA2 SFTPD TLR2 TLR4 TLR9
40 regulation of signaling receptor activity GO:0010469 10.05 CCL17 IFNG IL10 IL4 IL5
41 innate immune response GO:0045087 10 CD209 CLEC7A MBL2 SFTPD TLR2 TLR4

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 CCL17 IFNG IL10 IL4 IL5
2 mannose binding GO:0005537 9.4 CD209 MBL2
3 monosaccharide binding GO:0048029 9.37 SFTPA2 SFTPD
4 carbohydrate binding GO:0030246 9.35 CD209 CLEC7A MBL2 SFTPA2 SFTPD
5 signaling pattern recognition receptor activity GO:0008329 9.32 CLEC7A TLR2
6 lipopolysaccharide receptor activity GO:0001875 9.26 TLR2 TLR4
7 lipopolysaccharide binding GO:0001530 8.92 SFTPA2 SFTPD TLR2 TLR4

Sources for Aspergillosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....